August’s top stories: Implantable Wi-Fi devices, Myriad to buy Assurex Health
University of Washington researchers introduced implantable Wi-Fi devices and Myriad announced plans to acquire Assurax Health for 225m. Medicaldevice-network.com wraps-up the key headlines from August.
Researchers at the University of Washington (UW) introduced a technology which will enable devices such as brain implants, contact lenses and other electronic wearable devices to communicate with regular devices such as smartphones and watches.
The interscatter communication transforms Bluetooth signals into Wi-Fi transmissions over the air.
An interscatter device such as a smart contact lens converts Bluetooth signals emitted from the regular devices such as a smartwatch, into Wi-Fi transmissions which can be detected by a smartphone.
US-based molecular diagnostics company Myriad Genetics agreed to acquire informatics-based precision medicine company Assurex Health for $225m.
The potential transaction will be funded by Myriad through cash on hand and debt. An additional $185m will be paid based on performance-based milestone achievements.
Subject to customary closing conditions and regulatory approvals, the transaction is expected to be completed at the beginning of next year.
A report by Cambridge Consultants suggests that innovations and technical advances made in emerging markets will reshape the delivery of surgical care by 2030.
The report is based on the findings of a workshop recently held in Boston by Cambridge Consultants which analysed the effects of advances made in the healthcare system on the existing quality of surgical care.
Cambridge Consultants surgical innovation for emerging markets head Rahul Sathe said: “More than 85% of the world’s population lives in emerging markets, yet many of these people have no access to affordable quality healthcare, particularly complex treatment like surgery.
Hobart Group member, Molecular Dynamics, reported positive results from its first phase clinical trial of the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype.
Valiance X12 has been designed as a whole-body CZT SPECT/CT solution to generate scans compared to positron emission tomography (PET) at a higher speed, lower dose and reduced cost.
Its wide band capabilities facilitate multi-function imaging while it enhances productivity and image quality due to improved resolution and sensitivity which is a result of its Cadmium Zinc Telluride (CZT) based technology.
Innovate UK has provided funding for the research and clinical trials of a bio-active implant to treat post-operative infection following a total knee replacement (TKR).
It is expected to result a significant cost reduction incurred by the post-operative complications to the National Health Service (NHS), which is estimated to be £300m per year.
The programme is led by implant manufacturers MatOrtho and advanced metal coating developer the Wallwork Group.
The US Food and Drug Administration (FDA) approved two new devices to evaluate a patient's cognitive function following the diagnosis of a suspected brain injury or concussion.
The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the two devices which have been designed to detect any sign and symptom of a head injury.
The devices are intended to test the patient's cognitive skills such as word memory, reaction time and word recognition which can be affected by head injury.
US-based neurotechnology company Brain State Technologies presented a study which discusses the benefits of a wearable neurotechnology device for military personnel to address post traumatic stress disorder (PTSD).
The device will be designed to optimise the sleep quality of individuals suffering from trauma.
Studies suggest that PTSD is characterised by disturbed sleep which is one of the most difficult symptoms to treat.
Kemuri has been shortlisted for the Active and Assisted Living (AAL) Challenge Prize out of 200 healthcare companies.
The programme will award €50,000 to the best idea or product which leverages on internet connectivity and the Internet of Things (IoT) to enhance the quality of life of older people and enable them to survive socially and independently.
The finalists will showcase their ideas at a special Innovation Academy in Brussels which will be evaluated by the judges.
Siemens Healthcare Diagnostics secured the US Food and Drug Administration (FDA) emergency use authorisation (EUA) for its real-time PCR Zika Virus assay, the VERSANT Zika RNA 1.0 Assay (kPCR) Kit.
The VERSANT Zika RNA 1.0 Assay (kPCR) Kit can facilitate an early detection of the Zika virus.
Siemens molecular diagnostics head and vice-president Fernando Beils said: “The FDA’s emergency use authorisation of the VERSANT Zika RNA 1.0 Assay (kPCR) Kit from Siemens can lead us one step closer to stopping the spread of the Zika virus.
Ireland-based medical device company Medtronic introduced its MiniMed 630G system with SmartGuard technology in the US to treat people with diabetes.
The MiniMed 630G is fitted with a new insulin pump hardware platform and a new user-friendly design which assists in personalised diabetes management.
The waterproof pump design introduces bolus functionality and features a high-definition, full-colour screen which aids an easy navigation while enabling increased customisation with menus.